Trial Profile
A Phase II, Multi-center, Randomized, Double-blind, Placebo-controlled, Crossover Study to Evaluate the Pharmacodynamic Effect of Single and Multiple Oral Doses of AZD1446/ Placebo and a Single Dose of Donepezil on Quantified Electroencephalography and Event-Related Potentials in Patients With AD.
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 05 Apr 2022
Price :
$35
*
At a glance
- Drugs AZD 1446 (Primary) ; Donepezil
- Indications Alzheimer's disease
- Focus Pharmacodynamics
- Sponsors AstraZeneca
- 02 Apr 2022 This trial has been completed in France (End Date: 1 March 2011) according to European Clinical Trials Database record.
- 12 May 2011 Additional lead trial investigator identified as reported by ClinicalTrials.gov.
- 12 May 2011 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.